Arbor Research Collaborative for Health, Ann Arbor, MI.
Duke University School of Medicine, Durham, NC.
Am J Kidney Dis. 2021 Feb;77(2):245-254. doi: 10.1053/j.ajkd.2020.06.020. Epub 2020 Sep 21.
RATIONALE & OBJECTIVE: Optimizing vascular access use is crucial for long-term hemodialysis patient care. Because vascular access use varies internationally, we examined international differences in arteriovenous fistula (AVF) patency and time to becoming catheter-free for patients receiving a new AVF.
Prospective cohort study.
SETTING & PARTICIPANTS: 2,191 AVFs newly created in 2,040 hemodialysis patients in 2009 to 2015 at 466 randomly selected facilities in the Dialysis Outcomes and Practice Patterns Study (DOPPS) from the United States, Japan, and EUR/ANZ (Belgium, France, Germany, Italy, Spain, Sweden, United Kingdom, Australia, and New Zealand).
Demographics, comorbid conditions, dialysis vintage, body mass index, AVF location, and country/region.
Primary/cumulative AVF patency (from creation), primary/cumulative functional patency (from first use), catheter dependence duration, and mortality.
Outcomes estimated using Cox regression.
Across regions, mean patient age ranged from 61 to 66 years, with male preponderance ranging from 55% to 66%, median dialysis vintage of 0.3 to 3.2 years, with 84%, 54%, and 32% of AVFs created in the forearm in Japan, EUR/ANZ, and United States, respectively. Japan displayed superior primary and cumulative patencies due to higher successful AVF use, whereas cumulative functional patency was similar across regions. AVF patency associations with age and other patient characteristics were weak or varied considerably between regions. Catheter-dependence following AVF creation was much longer in EUR/ANZ and US patients, with nearly 70% remaining catheter dependent 8 months after AVF creation when AVFs were not successfully used. Not using an arteriovenous access within 6 months of AVF creation was related to 53% higher mortality in the subsequent 6 months.
Residual confounding.
Our findings highlight the need to reevaluate practices for optimizing long-term access planning and achievable AVF outcomes, especially AVF maturation. New AVFs that are not successfully used are associated with long-term catheter exposure and elevated mortality risk. These findings highlight the importance of selecting the best access type for each patient and developing effective clinical pathways for when AVFs fail to mature successfully.
优化血管通路的使用对长期血液透析患者的护理至关重要。由于血管通路的使用在国际上存在差异,我们研究了新建立的动静脉瘘(AVF)通畅率和导管非依赖性时间在接受新 AVF 的患者中的国际差异。
前瞻性队列研究。
2009 年至 2015 年,在 Dialysis Outcomes and Practice Patterns Study(DOPPS)中,在美国、日本和 EUR/ANZ(比利时、法国、德国、意大利、西班牙、瑞典、英国、澳大利亚和新西兰)的 466 个随机选择的设施中,为 2040 名血液透析患者中的 2191 个新建立的 AVF 进行了前瞻性队列研究。
人口统计学特征、合并症、透析年限、体重指数、AVF 位置和国家/地区。
原发性/累积 AVF 通畅率(从建立开始)、原发性/累积功能通畅率(从首次使用开始)、导管依赖时间和死亡率。
使用 Cox 回归估计结果。
在不同地区,患者的平均年龄为 61 至 66 岁,男性比例为 55%至 66%,中位透析年限为 0.3 至 3.2 年,在前臂建立的 AVF 分别占日本、EUR/ANZ 和美国的 84%、54%和 32%。由于 AVF 的成功使用较高,日本显示出较好的原发性和累积通畅率,而各地区的累积功能通畅率相似。AVF 通畅率与年龄和其他患者特征的关联较弱,或在不同地区之间差异较大。AVF 建立后导管依赖时间在 EUR/ANZ 和美国患者中要长得多,当 AVF 未成功使用时,近 70%的患者在 AVF 建立后 8 个月仍依赖导管。AVF 建立后 6 个月内未使用动静脉通路与随后 6 个月内 53%的死亡率升高相关。
残余混杂。
我们的研究结果强调需要重新评估优化长期血管通路规划和可实现 AVF 结局的实践,尤其是 AVF 成熟度。未成功使用的新 AVF 与长期导管暴露和高死亡率风险相关。这些发现突出了为每位患者选择最佳血管通路类型以及制定有效的临床途径的重要性,以应对 AVF 未能成功成熟的情况。